CRISPR screens: finding the switches behind brain inflammation
Instead of testing genes one at a time, CRISPR screens can silence thousands of genes at once. Here is how pooled and arrayed screens reveal what keeps astrocytes inflamed — and what calms them down.
When a brain scan lights up with inflammation, thousands of genes inside each cell are doing something different than they were the week before. Which of those genes are actually driving the inflammation — and which are just bystanders? Testing candidates one experiment at a time would take decades.
CRISPR screens collapse that timeline. In a single experiment, they can ask every gene in the genome the same question: what happens without you?
A volume knob, not a pair of scissors
Most people know CRISPR as molecular scissors that cut DNA. Screens usually use a gentler version: a “dead” Cas9 protein that can still find its target gene but cannot cut it. Fused to a repressor, it acts like a volume knob turned to zero — the gene stays in place, but its message is silenced. This flavor is called CRISPRi (the “i” is for interference).
A pooled screen scatters thousands of these silencing guides across a whole population of cells, then watches which cells survive a challenge or change their behavior. An arrayed screen is tidier: each guide gets its own well, so you know exactly which gene caused which effect.
What the screens found in astrocytes
Our work applied both approaches to human stem-cell-derived astrocytes, the brain’s support cells. A CRISPRi screen published in Nature Neuroscience silenced genes across astrocytes pushed into inflammatory states — and revealed regulators that decide which inflammatory program a cell enters. Some genes, it turned out, work as brakes; others as accelerators.
A separate arrayed knockout hunt went after a more specific question: which genes control GLUT1, the transporter that ferries glucose across the blood-brain barrier. The hits, published in Scientific Reports, point to levers that could one day be pulled in diseases where the barrier misbehaves.
Why screens matter for medicine
A screen is really a discovery engine: it converts “we think these hundred genes matter” into “these five do, here is the evidence.” The next step is validation — going back into organoids and barrier models to confirm the hits — and eventually, designing drugs or RNA-level interventions against the best targets.
That last step is where the stories on this site connect: once you know which switch controls inflammation, you can ask how to reach it — sometimes with an RNA edit instead of a drug.
New to the site? Start with the brain’s invisible proofreader, then see how reactive astrocytes fit in.